Detection of Hepatitis B Virus DNA Among Accepted Blood Donors in Nanjing, China

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2010 Aug 20

PMID 20718994

Citations 15

Authors

Yong Liu

Ping Li

Cuiping Li

Jinyong Zhou

Chao Wu

Yi-Hua Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Posttransfusion hepatitis B virus (HBV) infection still occurs although its incidence has been substantially reduced since the introduction of screening of hepatitis B surface antigen (HBsAg) in blood donors. This study aimed to investigate the occult HBV infection in accepted blood donors in Nanjing, China.

Results: The lower detection limit of the nested PCR in this study was estimated to be 20 copies/ml HBV DNA. The positive rate of occult HBV infection was 0.13% (5 of 2972) in the accepted blood donors. Sequencing data showed that the amplified HBV sequences were not identical each other and to the known sequences cloned in our laboratory, excluding the false-positive caused by cross-contamination. Phylogenetic analysis showed that the HBV in all five donors was genotype B; a single base deletion was detected in the S region of HBV DNA from one donor, and no mutation was observed in the "a" determinant of HBsAg from four other donors. All five donors were negative for anti-HBs and one was positive for anti-HBc.

Conclusions: The prevalence of occult HBV infection in the accepted blood donors in Nanjing, China is relatively high. The data would be meaningful in adapting strategy to eliminate posttransfusion HBV infection in China.

Citing Articles

A Recent Prevalence of Hepatitis B Virus (HBV) Genotypes and Subtypes in Asia: A Systematic Review and Meta-Analysis.

Bello K, Mat Jusoh T, Irekeola A, Abu N, Mohd Amin N, Mustaffa N Healthcare (Basel). 2023; 11(7).

PMID: 37046937 PMC: 10094200. DOI: 10.3390/healthcare11071011.

Prevalence of antibody to hepatitis B core antigen among hepatitis B surface antigen-negative blood donors in Ilorin, Nigeria: A cross-sectional study.

Ogunfemi M, Olawumi H, Olokoba A, Kagu M, Biliaminu S, Durowade K Malawi Med J. 2017; 29(1):32-36.

PMID: 28567194 PMC: 5442489. DOI: 10.4314/mmj.v29i1.7.

Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Ozoya O, Chavez J, Sokol L, Dalia S Ann Transl Med. 2017; 5(3):39.

PMID: 28251118 PMC: 5326643. DOI: 10.21037/atm.2016.12.25.

Serological Patterns and Molecular Characterization of Occult Hepatitis B Virus Infection among Blood Donors.

Lin H, Zhao H, Tang X, Hu W, Jiang N, Zhu S Hepat Mon. 2016; 16(10):e40492.

PMID: 27882070 PMC: 5116128. DOI: 10.5812/hepatmon.40492.

Occult Hepatitis B virus infection in previously screened, blood donors in Ile-Ife, Nigeria: implications for blood transfusion and stem cell transplantation.

Olotu A, Oyelese A, Salawu L, Audu R, Okwuraiwe A, Aboderin A Virol J. 2016; 13:76.

PMID: 27150469 PMC: 4859058. DOI: 10.1186/s12985-016-0533-3.

References

Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T . Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion. 2007; 48(2):286-94. DOI: 10.1111/j.1537-2995.2007.01522.x. View

Gerlich W, Glebe D, Schuttler C . Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat. 2007; 14 Suppl 1:16-21. DOI: 10.1111/j.1365-2893.2007.00912.x. View

Torbenson M, Thomas D . Occult hepatitis B. Lancet Infect Dis. 2002; 2(8):479-86. DOI: 10.1016/s1473-3099(02)00345-6. View

Zhang R, Wang L, Li J . Hepatitis B virus transfusion risk in China: proficiency testing for the detection of hepatitis B surface antigen. Transfus Med. 2010; 20(5):322-8. DOI: 10.1111/j.1365-3148.2010.01007.x. View

Kafi-Abad S, Rezvan H, Abolghasemi H, Talebian A . Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion. 2009; 49(10):2214-20. DOI: 10.1111/j.1537-2995.2009.02245.x. View

Gerlich W, Bremer C, Saniewski M, Schuttler C, Wend U, Willems W . Occult hepatitis B virus infection: detection and significance. Dig Dis. 2010; 28(1):116-25. DOI: 10.1159/000282074. View

Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P . Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?. Hepatology. 2001; 34(1):194-203. DOI: 10.1053/jhep.2001.25172. View

Shang G, Yan Y, Yang B, Shao C, Wang F, Li Q . Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China. Transfus Apher Sci. 2009; 41(1):3-7. DOI: 10.1016/j.transci.2009.05.001. View

Lelie N, Heaton A . Hepatitis B - a review of the role of NAT in enhancing blood safety. J Clin Virol. 2006; 36 Suppl 1:S1-2. DOI: 10.1016/s1386-6532(06)80001-6. View

10.

Wendel S, Levi J, Biagini S, Candotti D, Allain J . A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period. Transfusion. 2008; 48(8):1602-8. DOI: 10.1111/j.1537-2995.2008.01723.x. View

11.

Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain J . Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol. 2008; 48(6):1022-5. DOI: 10.1016/j.jhep.2008.02.016. View

12.

Chemin I, Trepo C . Clinical impact of occult HBV infections. J Clin Virol. 2006; 34 Suppl 1:S15-21. DOI: 10.1016/s1386-6532(05)80005-8. View

13.

Calderon G, Gonzalez-Velazquez F, Gonzalez-Bonilla C, Novelo-Garza B, Terrazas J, Martinez-Rodriguez M . Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico. Transfusion. 2009; 49(10):2200-7. DOI: 10.1111/j.1537-2995.2009.02248.x. View

14.

Utama A, Octavia T, Dhenni R, Miskad U, Yusuf I, Tai S . Hepatitis B virus genotypes/subgenotypes in voluntary blood donors in Makassar, South Sulawesi, Indonesia. Virol J. 2009; 6:128. PMC: 2732614. DOI: 10.1186/1743-422X-6-128. View

15.

Fang Y, Shang Q, Liu J, Li D, Xu W, Teng X . Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect. 2009; 58(5):383-8. DOI: 10.1016/j.jinf.2009.02.013. View

16.

Raimondo G, Pollicino T, Cacciola I, Squadrito G . Occult hepatitis B virus infection. J Hepatol. 2006; 46(1):160-70. DOI: 10.1016/j.jhep.2006.10.007. View

17.

Zhou Y, Wu C, Zhuang H . Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl). 2009; 122(1):98-102. View

18.

Hollinger F . Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat. 2007; 14 Suppl 1:11-5. DOI: 10.1111/j.1365-2893.2007.00910.x. View

19.

Hui C, Sun J, Au W, Lie A, Yueng Y, Zhang H . Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005; 42(6):813-9. DOI: 10.1016/j.jhep.2005.01.018. View

20.

Candotti D, Allain J . Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009; 51(4):798-809. DOI: 10.1016/j.jhep.2009.05.020. View